Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;42(2):85-92.
doi: 10.1007/s12029-011-9257-1.

Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma

Affiliations
Review

Acetylation as a transcriptional control mechanism-HDACs and HATs in pancreatic ductal adenocarcinoma

Günter Schneider et al. J Gastrointest Cancer. 2011 Jun.

Abstract

Introduction: Pancreatic ductal adenocarcinoma (PDAC) is one of the most malignant tumors with a dismal prognosis. Although our understanding of the carcinogenesis of the disease increases continuously, no effective conservative therapeutic strategies exist. Therefore, novel targets have to be defined at the experimental level. Histone deacetylases (HDACs), especially the class I isoenzymes HDAC1, 2, and 3, are highly expressed in PDAC.

Conclusion: This article summarizes the expression and functions of HDAC isoenzymes in PDAC, with a special focus on their promoter-specific mode of action. Although we have gained some molecular insight into the HDAC function in PDAC, less is known about the relevance of histone acetyltransferases (HATs) in PDAC. As an example, we will summarize function of the HAT p300, for which promoter-specific functions were described recently. Increasing the molecular insights into the functions of the acetylating and deacetylating machineries in PDAC are important, since this will lead to novel rationally based therapeutic strategies in the future.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Anticancer Res. 2008 May-Jun;28(3A):1531-9 - PubMed
    1. Nat Genet. 2000 Mar;24(3):300-3 - PubMed
    1. Anticancer Res. 2008 May-Jun;28(3A):1541-50 - PubMed
    1. J Clin Oncol. 2010 Mar 10;28(8):1358-65 - PubMed
    1. Gut. 2009 Oct;58(10):1399-409 - PubMed

Publication types

MeSH terms

Substances